This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundIn October 2018, a new heart transplant allocation policy was implemented in the United States to address inequalities. The rate of death postmultiorgan transplant was significantly higher in incidence curves under the new policy compared with the old policy era (logrankP=0.02). versus 4.9%) in the new policy era.
Aortic valve stenosis (AS) is often a contraindication to liver transplantation (LT). Despite the widely accepted impact of liver cirrhosis on aortic valve hemodynamics, the change in these parameters with LT or impact of AS on LT outcomes has not been described. m/s, p < 0.001) as compared to mild AS (1.5
In 2013 Kellogg’s funded British research that concluded “regular consumption of cereals might help children stay slimmer.” Assessing the potential for SenseCam to fight the current global health crises of increasing obesity and physical inactivity (2010-2013) Microsoft: £69K ATLAS trial of tamoxifen duration (1997-2018) AstraZeneca: £1.0M
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content